WallStSmart

Iovance Biotherapeutics Inc (IOVA)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Iovance Biotherapeutics Inc generates 43696% more annual revenue ($324.97M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -89.1%. IOVA earns a higher WallStSmart Score of 30/100 (F).

IOVA

Avoid

30

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -3.03

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IOVA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
65.7%10/10

Revenue surging 65.7% year-over-year

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

IOVA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-47.5%2/10

ROE of -47.5% — below average capital efficiency

Free Cash FlowQuality
$-66.28M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : IOVA

The strongest argument for IOVA centers on Revenue Growth, Debt/Equity. Revenue growth of 65.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : IOVA

The primary concerns for IOVA are EPS Growth, Piotroski F-Score, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

IOVA profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

IOVA is growing revenue faster at 65.7% — sustainability is the question.

IOVA generates stronger free cash flow (-66M), providing more financial flexibility.

Bottom Line

IOVA scores higher overall (30/100 vs 24/100) and 65.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Iovance Biotherapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?